[HTML][HTML] A narrative review of the clinical practicalities of bamlanivimab and etesevimab antibody therapies for SARS-CoV-2
R Nathan, I Shawa, I De La Torre, JM Pustizzi… - Infectious diseases and …, 2021 - Springer
The severity of coronavirus disease 2019 (COVID-19) ranges from mild to death, with high
morbidity and mortality rates reported amongst a vulnerable subset of patients termed high …
morbidity and mortality rates reported amongst a vulnerable subset of patients termed high …
A narrative review of the clinical practicalities of bamlanivimab and etesevimab antibody therapies for SARS-CoV-2.
R Nathan, I Shawa, I de la Torre, JM Pustizzi… - 2021 - cabidigitallibrary.org
The severity of coronavirus disease 2019 (COVID-19) ranges from mild to death, with high
morbidity and mortality rates reported amongst a vulnerable subset of patients termed high …
morbidity and mortality rates reported amongst a vulnerable subset of patients termed high …
A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2.
R Nathan, I Shawa, I De La Torre, JM Pustizzi… - … Diseases and Therapy, 2021 - go.gale.com
The severity of coronavirus disease 2019 (COVID-19) ranges from mild to death, with high
morbidity and mortality rates reported amongst a vulnerable subset of patients termed high …
morbidity and mortality rates reported amongst a vulnerable subset of patients termed high …
A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2.
R Nathan, I Shawa, I De La Torre… - … Diseases & Therapy, 2021 - search.ebscohost.com
The severity of coronavirus disease 2019 (COVID-19) ranges from mild to death, with high
morbidity and mortality rates reported amongst a vulnerable subset of patients termed high …
morbidity and mortality rates reported amongst a vulnerable subset of patients termed high …
A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2.
R Nathan, I Shawa, I De La Torre… - Infectious Diseases …, 2021 - europepmc.org
The severity of coronavirus disease 2019 (COVID-19) ranges from mild to death, with high
morbidity and mortality rates reported amongst a vulnerable subset of patients termed high …
morbidity and mortality rates reported amongst a vulnerable subset of patients termed high …
A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2
R Nathan, I Shawa, I De La Torre… - Infectious diseases …, 2021 - pubmed.ncbi.nlm.nih.gov
The severity of coronavirus disease 2019 (COVID-19) ranges from mild to death, with high
morbidity and mortality rates reported amongst a vulnerable subset of patients termed high …
morbidity and mortality rates reported amongst a vulnerable subset of patients termed high …
[HTML][HTML] A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2
R Nathan, I Shawa, I De La Torre… - Infectious Diseases …, 2021 - ncbi.nlm.nih.gov
The severity of coronavirus disease 2019 (COVID-19) ranges from mild to death, with high
morbidity and mortality rates reported amongst a vulnerable subset of patients termed high …
morbidity and mortality rates reported amongst a vulnerable subset of patients termed high …
A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2
R Nathan, I Shawa, I De La Torre… - Infectious Diseases …, 2021 - search.proquest.com
The severity of coronavirus disease 2019 (COVID-19) ranges from mild to death, with high
morbidity and mortality rates reported amongst a vulnerable subset of patients termed high …
morbidity and mortality rates reported amongst a vulnerable subset of patients termed high …